FinServ Acquisition II Equity Warrant Exp 17 Feb 2026 *W EXP 02/17/2026
Change company Symbol lookup
Select an option...
FSRXW FinServ Acquisition II Equity Warrant Exp 17 Feb 2026 *W EXP 02/17/2026
PTRA Proterra Inc
IH Ihuman Inc
LMT Lockheed Martin Corp
GBRGU Goldenbridge Acquisition Ltd
GBLX GB Sciences Inc
AROC Archrock Inc
AAPL Apple Inc
PCTY Paylocity Holding Corp
CPNG Coupang Inc
Go

Company profile

FinServ Acquisition Corp. II is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company focuses on the financial technology and financial services industries. The Company has no operations and has no revenues.

Price
Delayed
$0.7823
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 0 shares is on pace to be much lighter than FSRXW's 10-day average volume of 6,766 shares.

0

MONDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Sesen Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

4:28 pm ET October 15, 2021 (Newsfile) Print

Los Angeles, California--(Newsfile Corp. - October 15, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sesen Bio, Inc. ("Sesen Bio" or "the Company") (NASDAQ: SESN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between December 21, 2020 and August 17, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before October 18, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Sesen Bio's clinical trial for Vicineum suffered from more than 2,000 violations of trial protocols including 215 "major" violations. Three of the Company's clinical investigators were found guilty of "serious noncompliance," during the clinical trial including "back-dating data." The Company's clinical trials showed that Vicineum leaked into the body leading to side effects including liver failure. Vicineum was not likely to achieve FDA approval based on the clinical data that was submitted by the Company. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Sesen Bio, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99890

comtex tracking

COMTEX_395283536/2523/2021-10-15T16:28:11

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.